Global Retirement Partners LLC Has $53,000 Stock Position in Repligen Co. (NASDAQ:RGEN)

Global Retirement Partners LLC raised its position in Repligen Co. (NASDAQ:RGEN) by 54.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 368 shares of the biotechnology company’s stock after purchasing an additional 129 shares during the quarter. Global Retirement Partners LLC’s holdings in Repligen were worth $53,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. grew its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares in the last quarter. Resources Management Corp CT ADV acquired a new stake in Repligen in the third quarter valued at approximately $37,000. Quarry LP grew its position in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

NASDAQ:RGEN opened at $159.26 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a one year low of $113.50 and a one year high of $203.13. The company has a fifty day moving average price of $156.17 and a 200 day moving average price of $148.67. The stock has a market cap of $8.92 billion, a P/E ratio of -312.27, a PEG ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

RGEN has been the topic of several analyst reports. Canaccord Genuity Group increased their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Finally, Royal Bank of Canada upped their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.